尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白
Active Plasminogen Activator, Urokinase Receptor (uPAR)
CD87; PLAUR; PLAU-R; U-PAR; URKR; Monocyte Activation Antigen Mo3
- 編號(hào)APA141Hu04
- 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點(diǎn)6.4
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價(jià)格¥ 1224 ¥ 3060¥ 6120¥ 18360¥ 45900
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)

Urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored protein. Besides regulating proteolysis, uPAR could also activate many intracellular signaling pathways that promote cell motility, invasion, proliferation and survival through cooperating with transmembrane receptors. uPAR is overexpressed across a variety of tumors and is associated with cancer invasion and metastasis. ITGb1 has been identified as an interactor of uPAR, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human uPAR and recombinant human ITGb1. Briefly, uPAR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to ITGb1-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-uPAR pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human uPAR and recombinant human ITGb1 was shown in Figure 1, the EC50?for this effect is 0.165 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA141Hu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA141Hu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA141Hu04 | 尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA141Hu04 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA141Hu03 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA141Hu04 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB |
PAA141Hu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB; IHC |
PAA141Hu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB |
PAA141Hu03 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB; IHC; ICC; IP. |
LAA141Hu71 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
LAA141Hu83 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
LAA141Hu81 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
FAA141Hu81 | 抗尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標(biāo)記) | FCM |
MAA141Hu22 | 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA141Hu21 | 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體 | WB |
LAA141Hu82 | 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
SEA141Hu | 尿激酶型纖溶酶原激活因子受體(uPAR)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA141Hu | 尿激酶型纖溶酶原激活因子受體(uPAR)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
International Journal of Cancer | Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice[Wiley: source] |
Biomark Insights | Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with Autism[PubMed: PMC3623607] |
Biomarker insights | Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD)[PubMed: PMC3762604] |
Am J Emerg Med | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis[PubMed: 26615223] |
Archives of Clinical Infectious Diseases | Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis[Archcid: 26346] |
The American Journal of Emergency Medicine | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic Cavia (Guinea pig )idance of sepsis[science:S0735675715009559] |
Journal of Clinical and Experimental Hepatology | Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD)?…[10.1016:j.jceh.2018.02.001] |
Turkish journal of trauma & emergency surgery | The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis[Pubmed: 31475329] |
CELL TRANSPLANTATION | Predictive Value of Degranulating Factors of Neutrophils in Massive Cerebral Infarction[33787356] |